Denali Therapeutics Inc.
NASDAQ:DNLI
29.6 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Operating Activities: | |||||||||
| Net Income
| -145.224 | -325.991 | -290.581 | 71.136 | -197.614 | -36.24 | -88.185 | -86.652 | -16.788 |
| Depreciation & Amortization
| 16.726 | 10.383 | 8.593 | 8.531 | 7.991 | 7.415 | 3.082 | 1.469 | 0.121 |
| Deferred Income Tax
| -2.431 | 0 | 8.748 | 0.055 | -5.019 | 0 | 0 | 0.307 | 0 |
| Stock Based Compensation
| 108.102 | 99.847 | 85.247 | 50.351 | 38.378 | 18.791 | 4.409 | 2.951 | 0.479 |
| Change In Working Capital
| -289.926 | -24.03 | -20.412 | 288.401 | 4.175 | 62.891 | 3.305 | 4.286 | 0.426 |
| Accounts Receivables
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables
| 2.431 | 2.274 | 3.705 | -1.623 | 1.033 | -0.526 | 0.207 | 0.161 | 1.678 |
| Other Working Capital
| -292.357 | -26.304 | -24.117 | 290.024 | 3.142 | 63.417 | 3.098 | 4.125 | -1.252 |
| Other Non Cash Items
| -45.238 | -4.925 | -2.984 | -2.322 | 0.513 | -2.741 | 0.754 | 5.28 | 0.71 |
| Operating Cash Flow
| -357.991 | -244.716 | -211.389 | 416.152 | -151.576 | 50.116 | -76.635 | -72.359 | -15.052 |
| Investing Activities: | |||||||||
| Investments In Property Plant And Equipment
| -12.939 | -17.833 | -8.5 | -3.095 | -17.919 | -3.393 | -2.875 | -6.134 | -3.062 |
| Acquisitions Net
| -262.247 | 123.554 | 13.126 | 620.111 | -165.631 | 0 | 0 | 0 | 0 |
| Purchases Of Investments
| -1,813.7 | -1,115.04 | -1,422.938 | -1,285.468 | -369.696 | -557.93 | -179.789 | -226.87 | 0 |
| Sales Maturities Of Investments
| 2,075.947 | 991.486 | 1,409.812 | 665.357 | 535.327 | 273.901 | 141.498 | 14 | 0 |
| Other Investing Activites
| 262.247 | -123.554 | -13.126 | -620.111 | 165.631 | -284.029 | -38.291 | -212.87 | 0 |
| Investing Cash Flow
| 249.308 | -141.387 | -21.626 | -623.206 | 147.712 | -287.422 | -41.166 | -219.004 | -3.062 |
| Financing Activities: | |||||||||
| Debt Repayment
| 0 | -3.149 | -3.737 | -297.418 | 0 | 0 | 0 | 0 | -5 |
| Common Stock Issued
| 17.82 | 296.215 | 19.348 | 614.094 | 6.19 | 97.019 | 265.619 | 300.476 | 0.11 |
| Common Stock Repurchased
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities
| 0 | 17.604 | 3.737 | 318.073 | 6.19 | 97.019 | 30.704 | 300.476 | 48.744 |
| Financing Cash Flow
| 17.82 | 310.67 | 19.348 | 634.749 | 6.19 | 97.019 | 296.323 | 300.476 | 48.854 |
| Other Information: | |||||||||
| Effect Of Forex Changes On Cash
| -0.075 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Change In Cash
| -90.938 | -75.433 | -213.667 | 427.695 | 2.326 | -140.287 | 178.522 | 9.113 | 30.74 |
| Cash At End Of Period
| 127.106 | 219.544 | 294.977 | 508.644 | 80.949 | 78.623 | 218.375 | 39.853 | 30.74 |